Literature DB >> 21633642

p53 antibodies, metallothioneins, and oxidative stress markers in chronic ulcerative colitis with dysplasia.

Hala E Hamouda1, Soha S Zakaria, Saber A Ismail, Mahmoud A Khedr, Wael W Mayah.   

Abstract

AIM: To investigate the role of p53 antibodies (p53Abs), metallothioneins (MTs) and oxidative stress markers in the early detection of dysplasia in chronic ulcerative colitis (UC).
METHODS: The study included 30 UC patients, 15 without dysplasia (group II) and 15 with dysplasia (group III), in addition to 15 healthy volunteers (group I, control subjects). The enzyme-linked immunosorbent assay technique was used to measure serum p53Abs and MTs, while advanced oxidation protein products (AOPPs), and reduced glutathione (GSH) levels were measured by spectrophotometric method in all subjects.
RESULTS: In group II and group III compared to group I, there were significant increases in serum levels of AOPPs (145.94 ± 29.86 μmol/L and 192.21 ± 46.71 μmol/L vs 128.95 ± 3.06 μmol/L, P < 0.002 and P < 0.001, respectively), MTs (8.18 ± 0.35 μg/mL and 9.20 ± 0.58 μg/mL vs 6.12 ± 0.25 μg/mL, P < 0.05 and P < 0.05, respectively), and p53Abs (20.19 ± 3.20 U/mL and 34.66 ± 1.34 U/mL vs 9.42 ± 1.64 U/mL, P < 0.001 and P < 0.001, respectively). There were significantly higher levels of AOPPs (P < 0.05) and p53Abs (P < 0.001) in UC patients with dysplasia compared to those without dysplasia, while MTs showed no significant difference between the 2 groups (P > 0.096). In contrast, GSH levels showed a significant decrease in both patients' groups (1.87 ± 0.02 μmol/mL and 1.37 ± 0.09 μmol/mL vs 2.49 ± 0.10 μmol/mL, P < 0.05 and P < 0.05 in groups II and III, respectively) compared with group I, and the levels were significantly lower in group III than group II (P < 0.05). There was a positive correlation between AOPPs and both MTs (r = 0.678, P < 0.001) and p53Abs (r = 0.547, P < 0.001), and also between p53Abs and MTs (r = 0.739, P < 0.001). There was a negative correlation between AOPPs and GSH (r = -0.385, P < 0.001), and also between GSH and both MTs (r = -0.662, P < 0.001) and p53Abs (r = -0.923, P < 0.001).
CONCLUSION: Oxidative stress and oxidative cellular damage play an important role in the pathogenesis of chronic UC and the associated carcinogenetic process. p53Abs levels could help in early detection of dysplasia in these conditions.

Entities:  

Keywords:  Advanced oxidation protein products; Metallothionein; Reduced glutathione; Ulcerative colitis

Mesh:

Substances:

Year:  2011        PMID: 21633642      PMCID: PMC3103795          DOI: 10.3748/wjg.v17.i19.2417

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  42 in total

Review 1.  Epidemiology and the natural course of inflammatory bowel disease.

Authors:  P G Andres; L S Friedman
Journal:  Gastroenterol Clin North Am       Date:  1999-06       Impact factor: 3.806

Review 2.  Advanced glycoxidation end products in chronic diseases-clinical chemistry and genetic background.

Authors:  Marta Kalousová; Tomás Zima; Vladimír Tesar; Sylvie Dusilová-Sulková; Jan Skrha
Journal:  Mutat Res       Date:  2005-08-05       Impact factor: 2.433

3.  Serum p53 antibodies in patients with chronic inflammatory bowel disease.

Authors:  H Fricke; S Urban; N Noehl; C Folwaczny
Journal:  Gut       Date:  1998-06       Impact factor: 23.059

4.  Glutathione content of colonic mucosa: evidence for oxidative damage in active ulcerative colitis.

Authors:  E W Holmes; S L Yong; D Eiznhamer; A Keshavarzian
Journal:  Dig Dis Sci       Date:  1998-05       Impact factor: 3.199

Review 5.  Cancer surveillance in inflammatory bowel disease: new molecular approaches.

Authors:  Rosa Ana Risques; Peter S Rabinovitch; Teresa A Brentnall
Journal:  Curr Opin Gastroenterol       Date:  2006-07       Impact factor: 3.287

6.  Characterisation and clinicopathological correlates of serum anti-p53 antibodies in breast and colon cancer.

Authors:  D Coomber; N J Hawkins; M Clark; A Meagher; R L Ward
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

7.  Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure.

Authors:  V Witko-Sarsat; M Friedlander; T Nguyen Khoa; C Capeillère-Blandin; A T Nguyen; S Canteloup; J M Dayer; P Jungers; T Drüeke; B Descamps-Latscha
Journal:  J Immunol       Date:  1998-09-01       Impact factor: 5.422

8.  Expression of p53, bcl-2, and Ki-67 proteins in the inflammatory regenerative and dysplastic epithelial lesions of flat colonic mucosa.

Authors:  Svjetlana Radović; Zora Vukobrat-Bijedić; Ivan Selak; Mirsad Babić
Journal:  Bosn J Basic Med Sci       Date:  2006-02       Impact factor: 3.363

9.  The humoral response to the tumor-suppressor gene-product p53 in human cancer: implications for diagnosis and therapy.

Authors:  T Soussi
Journal:  Immunol Today       Date:  1996-08

10.  p53 mutation in patients with ulcerative colitis in rectal biopsy.

Authors:  H J Kim; S K Chang
Journal:  Korean J Intern Med       Date:  1998-07       Impact factor: 2.884

View more
  6 in total

1.  Role of oxidative stress & antioxidant defence in ulcerative colitis patients from north India.

Authors:  S V Rana; S Sharma; K K Prasad; S K Sinha; K Singh
Journal:  Indian J Med Res       Date:  2014-04       Impact factor: 2.375

2.  Protective Effect of Baicalin Against Experimental Colitis via Suppression of Oxidant Stress and Apoptosis.

Authors:  Jun Yao; Xu Cao; Ru Zhang; Ying-Xue Li; Zheng-Lei Xu; Ding-Guo Zhang; Li-Sheng Wang; Jian-Yao Wang
Journal:  Pharmacogn Mag       Date:  2016 Jul-Sep       Impact factor: 1.085

3.  Is Oxidative Stress Associated with Activation and Pathogenesis of Inflammatory Bowel Disease?

Authors:  Mahmut Yuksel; Ihsan Ates; Mustafa Kaplan; Mehmet Fettah Arikan; Yasemin Ozderin Ozin; Zeki Mesut Yalin Kilic; Canan Topcuoglu; Ertugrul Kayacetin
Journal:  J Med Biochem       Date:  2017-10-28       Impact factor: 3.402

Review 4.  Metallothioneins in Inflammatory Bowel Diseases: Importance in Pathogenesis and Potential Therapy Target.

Authors:  Anna Socha-Banasiak; Patrycja Sputa-Grzegrzółka; Jędrzej Grzegrzółka; Krzysztof Pacześ; Piotr Dzięgiel; Beata Sordyl; Hanna Romanowicz; Elżbieta Czkwianianc
Journal:  Can J Gastroenterol Hepatol       Date:  2021-04-24

5.  Histone deacetylase inhibitor givinostat has ameliorative effect in the colitis model.

Authors:  Cengiz Dibekoğlu; Oytun Erbaş
Journal:  Acta Cir Bras       Date:  2022-07-22       Impact factor: 1.564

6.  A Novel Role of Dapagliflozin in Mitigation of Acetic Acid-Induced Ulcerative Colitis by Modulation of Monocyte Chemoattractant Protein 1 (MCP-1)/Nuclear Factor-Kappa B (NF-κB)/Interleukin-18 (IL-18).

Authors:  Mohamed Kh ElMahdy; Samar A Antar; Ehab Kotb Elmahallawy; Walied Abdo; Hayfa Hussin Ali Hijazy; Ashraf Albrakati; Ahmed E Khodir
Journal:  Biomedicines       Date:  2021-12-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.